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Abstract
Background: OxyElite Pro (OEP) is a dietary supplement to increase metabolism which contains as key stimulant
the ingredient 1,3-dimethylamylamine (DMAA). Serious adverse effects have been reported after OEP consumption
however, these effects are related to poisoning or overdose. To our knowledge, no one studied the effects of OEP
at controlled doses. Thus, the aim of this study was to evaluate acute and chronic OEP affects, at controlled doses
in Wistar rats, on physical performance, metabolic parameters, liver injury markers and oxidative stress markers and
mitochondrial biogenesis in skeletal muscle.
Methods: Rats were divided in control, 4.3 mg OEP/kg, 12.9 mg OEP/kg and 25.8 mg OEP/kg. All groups were
submitted to supplementation with OEP for 4 weeks and the experimental protocols were performed 30 min after
the first OEP administration (acute response) and 30 min after the last OEP administration at the end of the forth
week (chronic response).
Results: Running distance and running time increased after acute administration of 12.9 mg OEP/kg (2.6-fold)
and 25.8 mg OEP/kg (2.8-fold). Since no effect on the exercise tolerance test was observed at the lower OEP
dose (4.3 mg OEP/kg), this group was removed from further analyzes. On other hand, running distance and
running time decreased after daily supplementation for 4 weeks also in both groups (64% in 12.9 mg OEP/kg
and 72% in 25.8 mg OEP/kg). Chronic supplementation at both 12.9 and 25.8 mg OEP/kg decreased TBARS
levels in soleus muscle (36 and 31%) and liver (43 and 25%). AOPP was also decreased by both doses in the
liver (39 and 45%). Chronic administration of the highest dose, 25.8 mg OEP/kg, was able to reduce mRNA
expression of PGC-1α in soleus muscle (25%). No effect was found in other analyses such as spontaneous
physical activity, body weight, food and water intake, hepatic toxicity, cardiac oxidative stress and mitochondrial DNA
amount.
Conclusion: Maximum and not recommended doses of OEP ingested acutely presented stimulating effect
on the ability to exercise. However, its daily consumption for 4 weeks showed antioxidant effects in soleus
muscle and liver which may have decreased the PGC-1α mRNA expression on soleus muscle and contributed
to the impaired performance in the exercise tolerance test.
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Background
Dietary supplements are a great business worldwide.
Since 2004 the supplements industry increased their
sales, reaching an approximate value of 61 billion in
2008 only in USA. The sale of dietary supplements con-
tinue to increase in popularity, with 80% of adults in the
United States buying at least 1 supplement yearly [1].
The number of supplements found on the market in-
creased from 4.000 in 1994 to more than 55.000 prod-
ucts in 2012 [2]. These supplements are sold with the
promise of losing weight and increase physical activity
performance [3–5]. Most of these dietary supplements
contain one or more ingredients capable of stimulating
the Central Nervous System (CNS).
OxyElite Pro (OEP) is a dietary supplement produced
by the USP Lab (USPLabs, Dallas, TX) and contains a
mixture of plant-derived extracts, commercialized in
order to aid in weight loss and improve physical per-
formance [5, 6]. The OEP contains a combination of sev-
eral ingredients that promises to increase metabolism
and lipolysis. Among its composition a key ingredient
1,3 dimethylamylamine, also known as germanium, gera-
namine or DMAA is found [6]. DMAA is a simple
aliphatic amine found naturally in geranium flowers
(Genus Geranium). It is a central nervous system stimu-
lant that induces transient sympathomimetic effects,
acting as a norepinephrine reuptake inhibitor and nor-
epinephrine releasing agent [6–8].
DMAA was initially used as a nasal decongestant
called Forthane® by the pharmaceutical laboratory Eli
Lilly, ending its use in 1983 [9]. Registered as gerana-
mine the DMAA reappeared on the market in 2006 as
an ingredient in various dietary supplements [10]. How-
ever, several adverse effects began to be associated with
the use of products containing DMAA. After these
reports, discussions on the origin of DMAA were
questioned as to the possibility of this substance be
of natural origin or not. Consequently, studies began
to investigate geranium plants to identify the presence
of DMAA and determine the amount of this sub-
stance. In contradiction, some studies found DMAA
in geranium plants (funded by USPlabs) [11, 12] and
others did not identify the DMAA being of native
origin [13, 14]. In addition, the amount of DMAA
found in plants was lower than the amount found in
dietary supplements.
In April 2013, the Food and Drug Administration
(FDA) banned the commercialization of dietary supple-
ments containing DMAA due to the controversy on the
amount of DMAA found in plants and into he supple-
ments [4]. However, DMAA has still been found in the
general public. DMAA was detected in 25% urine sam-
ples collected from portable street urinals in central
London [15, 16].
Although some studies have already been performed
in humans as described, only 1 study was performed in
animal model and only 1 study in cell culture [6, 10],
showing the lack of mechanistic studies. Also, studies
showing that those supplements are safe and well toler-
ated were from groups sponsored by its manufacturer,
the USP labs [1, 3, 17, 18]. On the other hand, those
studies showing serious adverse effects associated with
OEP consumption were associated with poisoning or in-
gestion of a huge or unadvertised amount of the supple-
ment. Thus, the aim of this study was to evaluate the
effects of known doses of OEP on physical performance,




Male Wistar Rats (Rattus Norvegicus Albinus)
6 weeks-old were obtained from the Federal Univer-
sity of Espirito Santo animal care, Brazil. Rats were
kept in groups of five in plastic cages with controlled
temperature (22–23 °C), light–dark cycle of 12:12-h,
with free access to food and water. All protocols and
surgical procedures used were in accordance with the
guidelines of the Brazilian College for Animal Experimen-
tation and were approved by the Ethics Committee of the
Federal University of Espirito Santo (CEUA-UFES, Proto-
col 007/2015).
OEP dosages were determined in accordance to doses
recommended on the label of the OEP: 1 capsule to
70 kg-adult body weight (i.e. 4.3 mg/kg). Animals were
randomly separated into four groups: control group
(Vehicle-5% tween20), 4.3 mg OEP/kg (equivalent to 1
capsule, the minimum recommended dosage per day),
12.9 mg OEP/kg (equivalent to 3 capsules, the maximum
recommended dosage per day) and 25.8 mg OEP/kg
(equivalent to 6 capsules, overdose and not recom-
mended). OEP was diluted in 5% Tween20 and orally
administrated by gavage.
Rats were daily supplemented for 4 weeks. Acute data
were obtained 30 min after the first OEP administration
while chronic data were obtained after 4 weeks supple-
mentation. The same animals were used in both proto-
cols. Since no difference was observed in the exercise
capacity after acute 4,3 mg OEP/kg administration, this
dose was not administered for 4 weeks.
At the end of the experimental period, rats were anes-
thetized with an i.p injection of a combination of
100 mg/kg ketamine and 10 mg/kg xylazine, and were
euthanized via intravenous (i.v) ketamine injection.
Plasma was collected and stored at−80 °C for later ana-
lysis. At the end of the protocol, skeletal muscle (soleus
and gastrocnemius), heart, liver and adrenal glands sam-
ples were surgically removed. The tissues were weighed,
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washed in a solution of Phosphate Buffered Solution and
stored at−80 °C.
Open field test
Open field test was used to assess spontaneous physical
activity as previous published by Rosic et al. [19]. The
open field apparatus consisted of a black acrylic enclosed
square arena of 43,2 cm × 43,2 cm closed by a wall of
30,5 cm high. At beginning of the test each rat was
placed in the center of the arena. Rat movements were
recorded by a digital video camera placed centrally
above the open field for 5 min and analyzed using
AnyMaze software. Spontaneous physical activity was
assessed 30 min after the first OEP administration (acute
response) and 30 min after the last OEP administration
at the end of the forth week protocol (chronic response).
Exercise Tolerance Test (ETT)
Exercise capacity was determined by graded treadmill
exercise test, a method used for detecting exercise in-
tolerance as previous used by our group [20]. Rats were
adapted to treadmill exercises for 3 consecutive days
with a gradual speed increase (7 m/min, 9 m/min and
13 m/min, without inclination, for 10 min each day).
Forty-eight hours after the adaptation period, rats were
placed in the exercise streak and allowed to acclimatize
for at least 30 min. Exercise began at 7 m/min with no
grade and increased by 3 m/min every 3 min thereafter
until exhaustion. The ETT was performed following the
open field test.
Food and water intake
Rats were placed in individual metabolic cages (Tecni-
plast 304) during 48 h for analysis of food and water
consumption as previous published by Berger et al. [21].
The first 24 h were used for adaptation and the follow-
ing 24 h were used to record food and water intake.
Metabolic cage was performed 30 min after the first
OEP administration (acute response) and 30 min after
the last OEP administration at the end of the forth week
protocol (chronic response).
Oxidative stress
The levels of lipid peroxidation were determined using
the thiobarbituric-acid reactive substances (TBARS)
spectrophotometric assay based on the reaction between
malondialdehyde (MDA) and triobarbituric acid (TBA)
as previous described by our group Leal et al. [22].
Briefly, the samples were homogeneized with trichoroa-
cetic acid and butylated hydroxytoluene. After being
vortexed, the samples were placed in dry bath and
then centrifuged. The upper phase was diluted with
triobarbituric acid and placed in dry bath for 30 min,
and the upper phase was read at 532 nm using a
spectrophotometer.
Additionally, the advanced oxidation protein products
(AOPP) assay protocol was used to evaluate the oxida-
tion of proteins as previous described [22]. Briefly, sam-
ples were diluted with phosphate buffer solution,
potassium iodide (KI) and acetic acid, vortexed for
6 min and then measured at 340 nm. Chloramine-T
absorbance at 340 nm was used as standard curve (0 to
100 μM). Total protein content was determined by the
Bradford method.
Toxicity
Alanine transaminase (ALT), aspartate transaminase
(AST) and γ-glutamyltransferase (GGT) enzymes activ-
ities were measured in plasma, using commercially avail-
able kits from Bioclin (Brazil), in accordance with the
manufactures’ instructions. A standard curve was con-
structed using stock solution of transaminases and the
substrates. All samples of transaminases were measured
at 505 nm and GGT was measured at 405 nm.
mRNA quantification using real-time PCR
The relative gene expression of Peroxisome proliferator-
activated receptor coactivator 1 alpha (PGC-1α) was an-
alyzed by real-time PCR. Frozen LV and skeletal muscles
samples were homogenized in Trizol and total RNA was
isolated according to the manufacturer’s instructions
(Invitrogen Life Technologies, Strathclyde, UK). Total
RNA concentration and integrity were assessed and real-
time PCR was performed. The mRNA expression was
assessed by oligonucleotides primers as follows: PGC-1α,
5′-ACC AAA CCC ACAGAGAACAG-3′ and 5′-GGGT
CAGAGGAAGAGATAAAGTTG-3′. The expression of
cyclophilin A, 5′-AATGCTGGACCAAACACAAA-3′
and 5′-CCT TCTTTCACCTTCCCAAA-3′; was mea-
sured as an internal control for sample variation in RT
reaction. Quantification of the target genes expression
was performed with a SYBRgreen PCR Master Mix
(Applied Biosystem, CA, USA). The relative expression
of the mRNA was performed by real-time PCR in the
ABI PRISM 7700 Sequence Detection System (Applied
Biosystem).
Mitochondrial DNA assay
Mitochondrial to nuclear DNA ratio was used to esti-
mate mitochondrial copy number in skeletal muscle tis-
sue. Skeletal muscles DNA were extracted using Trizol
following manufacturer instructions (Invitrogen Life
Technologies, Strathclyde, UK). DNA template was
amplified by real-time PCR to determine relative mito-
chondrial and nuclear DNA quantity using SYBRgreen
PCR Master Mix (Applied Biosystem, CA, USA). The
following primers for ND1 gene (NADH dehydrogenase
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subunit 1) 5′-TCGGAGCCCTACGAGCCGTT-3′ and
5′-AGGGAGCTCGATTTGTTTCTG-3′; and for
nucleus-encoded 18S RNA gene, 5′-TAGTTGGATCT
TGGGAGCGGG-3′ and 5′-CCGCGGTCCTATTCCAT
TATT−3 were used. The expressions of the mitochon-
drial and nuclear DNAs were performed by real-time
PCR in the ABI PRISM 7700 Sequence Detection
System (Applied Biosystem).
Statistical analysis
The values are expressed as means ± SEM. ETT, Open
Field and Body weight were analyzed by two-way ana-
lysis of variance (ANOVA) for repeated measures
followed by Bonferroni’s post hoc test. Food and water
intake, AST, ALT and GGT, and oxidative stress were
analyzed by one-way analysis of variance (ANOVA)
followed by Bonferroni’s post hoc test. A value of p < 0.05
was considered statistically significant. Statistical soft-
ware SPSS version 22.0 was used for all analysis.
Results
Exercise Tolerance Test (ETT)
OEP stimulatory effect on exercise capacity was stud-
ied using the ETT. Figure 1 shows ETT after acute
and chronic OEP supplementation. Running distance
(Control, 118 ± 16; 4.3 mg OEP/kg, 159 ± 37; 12.9 mg
OEP/kg, 313 ± 42; 25.8 mg OEP/kg, 334 ± 48, meters,
p < 0.01, Fig. 1a) and running time (Control, 10.7 ±
0.9; 4.3 mg OEP/kg, 13.9 ± 1.9; 12.9 mg OEP/kg, 20.5
± 1.7; 25.8 mg OEP/kg, 21.1 ± 2.3, minutes, p < 0.01,
Fig. 1b) increased only after acute 12.9 mg/kg and
25.8 mg OEP/kg administration. No difference was
observed in 4.3 mg OEP/kg and thus this group was
not maintained in the chronic protocol.
When rats were daily supplemented for 4 weeks with
12.9 mg/kg or 25.8 mg/kg OEP, running distance (Con-
trol, 228 ± 66; 12.9 mg/kg OEP, 79 ± 6; 25.8 mg/kg OEP,
65 ± 4, meters, p < 0.01, Fig. 1a) and running time
(Control, 16 ± 3.2; 12.9 mg/kg OEP, 8.3 ± 0.5; 25.8 mg/kg
OEP, 7.4 ± 0.3, minutes, p < 0.01, Fig. 1b) decreased com-
pared to control group.
These data suggest a positive effect of acute OEP sup-
plementation but a negative effect on exercise capacity
when OEP is administered continuously for 4 weeks
(chronic).
Spontaneous physical activity
Spontaneous physical activity was measured using the
open field test (Fig. 2). No significant difference was ob-
served among groups in any of the parameters analyzed:
total running distance (Fig. 2a), mobile time (Fig. 2b)
and total lines crossed (Fig. 2c). Although not statisti-
cally different from Control group, there was a clear
tendency to increase spontaneous physical activity after
acute OEP supplementation at dose of 12.9 mg/kg OEP
while there was tendency to decrease spontaneous phys-
ical activity when the higher dose of OEP was supple-
mented for 4 weeks (Fig. 2, black bars).
Metabolic parameters and tissue mass
OEP is also a well-known dietary supplement for weight
loss. Body weight was analyzed throughout the 4 weeks
protocol while water and food intake were analyzed dur-
ing the first 24 h after the first OEP administration
(acute) and during 24 h after the last week of the
chronic administration protocol (Table 1).
Body weight was not different among groups at the
beginning or at the end of the protocol (Table 1). In
agreement, no difference in food or water intake was
observed among groups after acute administration or
after 4 weeks OEP supplementation measured by the
metabolic cage (Table 1). Altogether there is no evidence
that either acute or chronic OEP supplementation
Fig. 1 Effect of OEP supplementation on exercise capacity. a Total distance, b Total time. Data are expressed as mean ± SEM. OEP, Oxyelite Pro.
*p < 0.05 vs. Control group; #p < 0.05 vs. 4.3 mg/kg OEP group. Acute, a single OEP administration; Chronic, 4 weeks of daily OEP administration
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inhibits appetite or aids to decrease body weight at least
in normal feed rats.
Also, at the end of the chronic protocol (4 weeks),
gastrocnemius (Control, 4.3 ± 0.13; 12.9 mg/kg OEP,
4.4 ± 0,13; 25.8 mg/kg OEP, 4.6 ± 0.16, g/BW), soleus
(Control, 0.41 ± 0.010; 12.9 mg/kg OEP, 0.45 ± 0.012;
25.8 mg/kg OEP, 0.43 ± 0.014, mg/BW), heart tissue
(Control, 3.1 ± 0.05; 12.9 mg/kg OEP, 3.2 ± 0.06;
25.8 mg/kg OEP, 3.1 ± 0.06, g/BW), and adrenal
glands (Control, 0.081 ± 0.004; 12.9 mg/kg OEP, 0.078
± 0.005; 25.8 mg/kg OEP, 0.073 ± 0.004, mg/BW) were
weighed and no differences among groups were
observed.
Liver injury markers
Cases of acute hepatitis and liver injury were related to
the use of OEP, however the amount of OEP ingestion
was reported as unknown or at high doses [4, 5, 23].
Other studies with long-term supplementation but with
known amount of OEP found no difference in liver in-
jury markers (AST, ALT and GGT) [3, 17, 24].
Circulating liver injury markers ASL, ALT and Gama-
GT were also measured at the end of the chronic proto-
col. Fig. 3a shows similar levels of AST (Control, 54 ± 3;
12.9 mg/kg OEP, 55 ± 5; 25.8 mg/kg OEP, 55 ± 2, U/ml)
and ALT (Control, 36 ± 4; 12.9 mg/kg OEP, 37 ± 6;
25 mg/kg OEP, 31 ± 2, U/ml) among groups, while Fig. 3b
shows no differences in the Gama-GT levels (Control,
6.2 ± 0.4; 12.9 mg/kg OEP, 6.9 ± 0.5; 25.8 mg/kg OEP 6.4
± 0.4, U/ml).
Oxidative stress parameters
Tissue and circulating lipid peroxidation (TBARS,
Fig. 4a) and protein oxidation (AOPP, Fig. 4b) were ana-
lyzed after 4 weeks OEP supplementation. Plasma,
TBARS and AOPP was similar among groups.
Also, red and white gastrocnemius, and heart were
similar among groups. However, OEP at both doses
Fig. 2 Effect of OEP supplementation on spontaneous locomotor activity. a Total distance, b Time Mobile 70%, c Number of crossings. Data are
expressed as mean ± SEM. OEP, Oxyelite Pro. Acute, a single OEP administration; Chronic, 4 weeks of daily OEP administration
Table 1 Effect of OEP supplementation
Group Body Weight (BW) (g) Food intake/BW (mg/g) Water intake/BW (ml/g)
0 WK 4 WK Acute Chronic Acute Chronic
Control 177 ± 9 318 ± 9 102 ± 5 73 ± 5 0.145 ± 0.009 0.104 ± 0.006
12.9 mg/kg OEP 176 ± 9 314 ± 9 98 ± 5 77 ± 6 0.137 ± 0.005 0.111 ± 0.008
25.8 mg/kg OEP 163 ± 9 298 ± 8 99 ± 5 65 ± 7 0.143 ± 0.010 0.098 ± 0.007
OEP Oxyelite Pro. Acute, a single OEP administration; Chronic, 4 weeks of daily OEP Administration. Data are expressed as mean ± SEM
Analysis on body weight, and food and water intake
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Fig. 3 Effect of OEP supplementation on liver injury markers. a Aspartate Transaminase, AST; and Alanine Transaminase, ALT; b γ-glutamyltransferase,
Gama-GT. Data are expressed as mean ± SEM. OEP, Oxyelite Pro
Fig. 4 Effect of OEP supplementation on circulating and tissue oxidative stress markers. a Lipid peroxidation, b Protein oxidation. Data are
expressed as mean ± SEM. TBARS, thiobarbituric-acid reactive substances; AOPP, advanced oxidation protein products; *p < 0.05 vs. Control group
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decreased lipid peroxidation in soleus muscle (12.9 mg/kg,
36%; 25.8 mg/kg, 31%) while only a tendency to decrease
was observed on protein oxidation (12.9 mg/kg, 20%;
25.8 mg/kg, 15%; p = 0.11).
Hepatic oxidative stress markers were also decreased
by both doses (TBARS; 43% in 12.9 mg/kg OEP and 25%
in 25.8 mg/kg OEP; and AOPP; 39% in 12.9 mg/kg OEP
and 45% in 25.8 mg/kg OEP).
Mitochondrial Biogenesis
PGC-1α mRNA expression (Fig. 5a) ND1 DNA amount
(Fig. 5b) were measured after 4 weeks of OEP supple-
mentation in soleus muscle, which has predominantly
oxidative fibers. PGC-1α mRNA expression decreased
25% in 25.8 mg/kg OEP group compared to control
group, but no difference was observed in 12.9 mg/kg
OEP group (Fig. 5a). ND1 DNA expression, marker of
total mitochondria content, was not modified among
groups (Fig. 5b).
Discussion
The findings from our study indicate that a single OEP
administration stimulated exercise performance (12.9
and 25.8 mg/kg), while chronic administration for
4 weeks of OEP decreased physical activity. Chronic
administration of OEP decreased oxidative stress
markers in soleus and liver tissues and decreased PGC-
1α mRNA expression. Lastly, OEP supplementation did
not change body weight, food and water intake, hepatic
injury markers (AST, ALT, Gama-GT) and skeletal
muscle total mitochondria amount.
OEP was mainly sold as fat burner and to assist in
rapid weight loss. In the present study we found no dif-
ference in body weight and food intake of the animals
supplemented with OEP. However, data found in the
literature are controversial on this subject. The effect of
OEP in reducing body weight and appetite was described
with 1 or 2 serving doses during 8 weeks by McCarthy
et al. [3], and after 2 weeks by Farney et al. [24]. How-
ever, it is noteworthy that the subjects of both studies
were regularly engaged in physical activity protocols
(which may have contributed to the weight loss) and
both studies were financed by USP Labs, the OEP manu-
facturer. Also, our results corroborate with data found
by Whitehead et al. [17], that no effect on body weight
was observed with supplementation of 1–3 serving OEP
during a period of 10 weeks without exercise training.
In our study, OEP showed no significant effect on
spontaneous locomotor activity. Although none has yet
studied OEP on spontaneous locomotor activity before,
Dolan et al. [10] studied the effects of isolated DMAA,
one of several ingredients in OEP, on mice spontaneous
activity. The authors observed that acute DMAA admin-
istration induced depressant effects within 0 to 30 min
which lasted for 50 to 70 min, but increased locomotor
activity after 120 to 180 min. This apparently disparate
data may be attributed to the fact that the dietary sup-
plement OEP has undetermined amount of DMAA and
also has caffeine on its formulation, which biased this
comparison.
Acute OEP administration at both 12.9 and 25.8 mg/
kg doses but not 4.3 mg/kg OEP increased exercise cap-
acity. Bloomer et al. [25] did not observe effect on run-
ning time in humans after acute ingestion of DMAA or
its combination with caffeine. However, the authors
reported that their results may have been biased due to
previously daily use of caffeine throughout the protocol
informed by the participants. Stimulatory effects of acute
ingestion of 6 mg/kg caffeine in rats and 5 mg/kg caf-
feine in humans has been demonstrated [26]. Also, acute
ingestion of 3 mg/kg caffeine or more is capable to im-
prove physical performance and endurance in humans
and animals [27]. Due to the lack of data explaining
DMAA effects, these findings with caffeine from
Fig. 5 Effect of OEP supplementation on mitochondrial biogenesis markers. a PGC-1α mRNA expression, b ND1 DNA amount. Data are
expressed as mean ± SEM. PGC-1α, peroxisome proliferator–activated receptor coactivator 1-alpha; ND1, NADH dehydrogenase subunit 1;
*p < 0.05 vs. Control group
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literature could at least partially explain our results. Each
OEP capsule contain 100 mg of caffeine and conse-
quently the dosage used in both studied groups with
higher concentration of OEP had at least 3 mg/kg of
caffeine, the necessary dose to increase physical activity
acute consumption [26, 27]. Thus, we believe that the
stimulatory effect observed after acute OEP administra-
tion is more likely due to caffeine in the supplement
instead of the DMAA amount.
Oppositely to findings from acute administration,
4 weeks of OEP harmed exercise performance. Vaughan
et al. [6] observed increase in PGC-1α mRNA and pro-
tein expression, and mitochondrial biosynthesis in skel-
etal muscle cells after 24 and 48 h of OEP incubation.
We found, in vivo, decreased PGC-1α mRNA expression
and unchanged mitochondrial content in the soleus
muscle, the main oxidative muscle of rat hind limb. Data
from both studies are difficult to compare since they
used a cell culture model and doses of OEP that cannot
be translated to the recommended doses in humans [6].
The antioxidant effect of OEP observed in our data
(reduced levels of MDA and AOPP in soleus muscle and
liver) may at least partially explain the decreased exer-
cise performance and PGC1α expression. PGC-1α is a
major regulator of energy metabolism and of mitochon-
drial biogenesis [28]. ROS are essential signaling mole-
cules that contribute to up-regulation for the expression
of several genes, including genes related to mitochon-
driogenesis [29]. There is evidence for an antioxidant
role of caffeine. Barcelos et. al. [30] showed that long-
term caffeine consumption reduced MDA levels in the
liver of exercise-trained rats [30], while Gomez-Cabrera
et al. [29] showed that 8 weeks of antioxidant supple-
mentation decreases endurance capacity (running time),
mitochondriogenesis and expression of key transcription
factors involved in mitochondrial biogenesis. However,
there are also studies demonstrating that caffeine in-
creases mitochondrial biogenesis markers as PGC-1α
and improves mitochondrial function and biogenesis
[31–33]. In addition, we cannot exclude the antioxidant
effects of OEP as previous described by McCarthy et al.
[3]. The authors observed lower plasmatic MDA levels
than placebo after OEP supplementation for 8 weeks
with 2 serving doses. Finally, since OEP contains a
mixture of ingredients we cannot exclude possible anti-
oxidant effects of other ingredient in the OEP formula.
Serious effects reported in the literature have been as-
sociated with use of products containing DMAA which
include tachycardia, nausea, vomiting, agitation, tremor,
dizziness, headache, confusion, drowsiness, chest pain,
palpitations, slurred speech [24, 34]. More serious and
life-threatening effects also have been reported, such as
acute myocardial infarction [35], cardiac arrest [36],
hemorrhage stroke [37–39] and death [16, 40]. In
addition, hepatotoxic effects were associated with the
use of OEP as: acute hepatitis and liver injury [23]. How-
ever, the doses used in these studies are high or un-
known and, in many cases, were associated with the use
of alcohol, other drugs or strenuous physical exercise.
On the other hand, similar to our findings, other studies
have observed no difference in the liver injury markers
(AST, ALT and GGT) [3, 17, 24, 25]. Differently from
the studies that observed hepatotoxicity effects, these
studies also used controlled does of OEP recommended
in the product label and were not associated with any
other drugs.
In summary, our study is the first one to use the rec-
ommended dose of OEP in animal model. We did not
observe such adverse effects related on literature mainly
because those responses are associated with unknown or
uncontrolled doses of OEP consumption. Also, we did
not observe the weight loss effect of OEP as promised in
the product label. On the other hand we observed that
acute administration of OEP increased physical perform-
ance, while its chronic administration for 4 weeks de-
creased its performance. We believe that the antioxidant
effect, observed by decreased TBARS and MDA, may
have contributed to the decreased PGC-1a expression
and thus decreased aerobic performance in chronic con-
sumption. Another possible mechanism is the rats toler-
ance to the supplement compounds, mainly to the
caffeine as already demonstrated [41].
One limitation of this study was that our experiments
were performed using a non-obese rat model. It would
also be interesting to examine the effects of OEP in
obese or overweight rat model. Further research is
needed to elucidate the effects of OEP on these models.
Conclusion
Our results suggest that doses maximum and not rec-
ommended of OEP ingested acutely presents a stimulat-
ing effect on the ability to exercise. However, the use of
these doses for 4 weeks showed antioxidant effects in
the soleus muscle and liver. Also, consumption of doses
greater than the recommended amount may have con-
tributed to suppressed soleus PGC-1α mRNA expression
and reduced physical performance of supplemented
animals.
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